<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Schmitt MM</submitter><funding>Intramural NIH HHS</funding><pagination>e131</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9004485</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>2(4)</volume><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a prototypic monogenic autoimmune disorder caused by AIRE deficiency-mediated impaired central immune tolerance. Although multiple endocrine and non-endocrine tissues are affected in APECED, the colon is an uncommon target of autoimmune attack. Mycophenolate is a potent immunomodulatory medication that is used to treat autoimmune manifestations in patients with APECED and other autoimmune diseases.&lt;h4>Methods&lt;/h4&gt;We reviewed the clinical, laboratory, genetic, histological, and treatment data of mycophenolate-induced colitis in our cohort of 104 APECED patients.&lt;h4>Discussion&lt;/h4>Among 10 mycophenolate-treated APECED patients, four (40%) developed reversible biopsy-proven mycophenolate-induced co</pubmed_abstract><journal>JPGN reports</journal><pubmed_title>Mycophenolate-Induced Colitis in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Patients.</pubmed_title><pmcid>PMC9004485</pmcid><funding_grant_id>ZIA AI001175</funding_grant_id><pubmed_authors>Schmitt MM</pubmed_authors><pubmed_authors>Quezado MM</pubmed_authors><pubmed_authors>Ferre EMN</pubmed_authors><pubmed_authors>Lionakis MS</pubmed_authors><pubmed_authors>Heller T</pubmed_authors><pubmed_authors>De Melo MS</pubmed_authors><pubmed_authors>Cooper MA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Mycophenolate-Induced Colitis in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Patients.</name><description>&lt;h4>Introduction&lt;/h4>Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a prototypic monogenic autoimmune disorder caused by AIRE deficiency-mediated impaired central immune tolerance. Although multiple endocrine and non-endocrine tissues are affected in APECED, the colon is an uncommon target of autoimmune attack. Mycophenolate is a potent immunomodulatory medication that is used to treat autoimmune manifestations in patients with APECED and other autoimmune diseases.&lt;h4>Methods&lt;/h4&gt;We reviewed the clinical, laboratory, genetic, histological, and treatment data of mycophenolate-induced colitis in our cohort of 104 APECED patients.&lt;h4>Discussion&lt;/h4>Among 10 mycophenolate-treated APECED patients, four (40%) developed reversible biopsy-proven mycophenolate-induced co</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Nov</publication><modification>2025-04-04T22:32:26.763Z</modification><creation>2025-02-19T03:23:46.893Z</creation></dates><accession>S-EPMC9004485</accession><cross_references><pubmed>35425944</pubmed><doi>10.1097/pg9.0000000000000131</doi></cross_references></HashMap>